; (2) educate pregnant and lactating women, their families, and health care professionals on the importance of enrolling in registries and clinical trials; and (3) inform pregnant and lactating women, their families, and health care professionals about the general requirements, commitments, and benefits associated with participating in a registry or clinical trial. (b) Requirements The Secretary, acting through the Director of the National Institutes of Health, and in consultation with the Commissioner of Food and Drugs and the heads of other relevant Federal departments and agencies, shall ensure that the clearinghouse under subsection (a)— (1) is accessible by means of the internet; (2) is updated on a regular basis, not less than quarterly; (3) is designed for consumers, incorporates a user-friendly interface, and is searchable; (4) includes links to related public and private sector resources on registries and clinical trials described in subsection (a); and (5) is available to the public by October 1, 2025. (c) Planning (1) In general In establishing the clearinghouse under subsection (a), the Secretary, shall— (A) develop criteria for which registries and clinical trials are eligible for listing in the clearinghouse under subsection (a); (B) establish a procedure for archiving closed registries and clinical trials; and (C) identify educational resources needed for the clearinghouse. (2) Public input The Secretary shall solicit public input on content to be included in the clearinghouse under subsection (a). (d) Authorization of appropriations To carry out this section, there are authorized to be appropriated— (1) $4,000,000 for the period of fiscal years 2024 through 2025